Medical Marijuana - Cannabidiol – Pipeline Insight, 2021

DelveInsights, Medical Marijuana - Cannabidiol Pipeline Insight, 2021, report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Medical Marijuana - Cannabidiol Understanding
Medical Marijuana - Cannabidiol: Overview
The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions. The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications. Since it contains chemicals it may help in treating a wide range of illnesses and symptoms; many people argue that it should be legal for medical purposes. A growing number of states have legalized marijuana for medical use. Medical marijuana is the medical use of Cannabis sativa or Cannabis indica plant to relieve symptoms of, or treat diseases and conditions. The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. THC can increase appetite and reduce nausea. THC may also decrease pain, inflammation (swelling and redness), and muscle control problems. Unlike THC, CBD is a cannabinoid that does not make people "high." These drugs are not popular for recreational use because they are not intoxicating. It may be useful in reducing pain and inflammation, controlling epileptic seizures, and possibly even treating mental illness and addictions. The FDA approved a CBD-based liquid medication called Epidiolex for the treatment of two forms of severe childhood epilepsy, Dravet syndrome and LennoxGastaut syndrome.

"Medical Marijuana - Cannabidiol - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medical Marijuana - Cannabidiol pipeline landscape is provided which includes the disease overview and Medical Marijuana - Cannabidiol treatment guidelines. The assessment part of the report embraces, in depth Medical Marijuana - Cannabidiol commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medical Marijuana - Cannabidiol collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Medical Marijuana - Cannabidiol R&D. The therapies under development are focused on novel approaches to treat/improve Medical Marijuana - Cannabidiol.

Medical Marijuana - Cannabidiol Emerging Drugs Chapters
This segment of the Medical Marijuana - Cannabidiol report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Medical Marijuana - Cannabidiol Emerging Drugs
BX-1: Bionorica SE
BX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of -THC, the primary psychoactive component of cannabis. The drug is currently in phase III stage of development for the treatment of spasticity in patients with multiple sclerosis not showing sufficient response to their current anti-spasticity treatment.

Lenabasum: Corbus Pharmaceuticals
Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells.

THX-110: Therapix Biosciences
THX-110 is a being developed by Therapix Biosciences. The drug candidate platform is for the treatment of symptoms related to Tourette syndrome (TS), as well as obstructive sleep apnea (OSA) and chronic pain. Therapix is seeking orphan drug designation for this compound. The THX-110 program takes a unique approach to cannabinoid formulation using the Entourage Effect hypothesis (i.e., in which endocannabinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. The drug is currently in phase II stage of development.

Cannabis oil: TO Pharmaceuticals
TO Pharma is developing next-generation cannabinoid therapies for debilitating diseases. TO pharmaceuticals is developing Cannabis oil, and currently, it is in phase II stage of development for the treatment of hidradenitis suppurativa and agitation related to dementia. The cannabis oil is made out of extract from the Avidekel strain and olive oil. Avidekel oil containing 9-Tetra-Hydrocannabinol (9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% 9-THC. Each Avidekel oil drop is approximately 0.04 mL in volume containing about 12 mg CBD and 0.6 mg 9-THC. The oil is in the form of drops to be administered orally.

VSN16R: Canbex Therapeutics
VSN16R is currently in phase II stage of development for the treatment of spasticity in people with multiple sclerosis. The orally active small molecule compound is being developed by Canbex Therapeutics, a spin-off of University College London (UCL). Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial. In the Phase I study, 72 healthy volunteers were enrolled in a placebo-controlled, single ascending- and multiple-ascending dose design.

INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product. The Phase 2 study, 755-201-EB, is designed to enroll up to 20 patients, conservatively within 10-12 months, and will take place at 10 pre-qualified clinical sites in several countries. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period.
Further product details are provided in the report..

Medical Marijuana - Cannabidiol: Therapeutic Assessment
This segment of the report provides insights about the different Medical Marijuana - Cannabidiol drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Medical Marijuana - Cannabidiol
There are approx. 25+ key companies which are developing the therapies for Medical Marijuana - Cannabidiol. The companies which have their Medical Marijuana - Cannabidiol drug candidates in the most advanced stage, i.e. Phase III include, Bionorica SE.

Phases
DelveInsights report covers around 50+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Medical Marijuana - Cannabidiol pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Medical Marijuana - Cannabidiol: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medical Marijuana - Cannabidiol therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medical Marijuana - Cannabidiol drugs.

Medical Marijuana - Cannabidiol Report Insights
Medical Marijuana - Cannabidiol Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Medical Marijuana - Cannabidiol Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Medical Marijuana - Cannabidiol drugs?
How many Medical Marijuana - Cannabidiol drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medical Marijuana - Cannabidiol?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Medical Marijuana - Cannabidiol therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Medical Marijuana - Cannabidiol and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Tetra Bio-Pharma
Corbus Pharmaceuticals
Bionorica SE
e3D Pharma
TO Pharmaceuticals
Therapix Biosciences
ANANDA Scientific
Daisy Pharma Opioid Venture
Canbex Therapeutics
InMed Pharmaceuticals
Botanix Pharmaceuticals
Centrexion Therapeutics
Tilray
One World Cannabis
Epm Group
Zelira Therapeutics
Pascal Biosciences
Cannovex
Can-Fite Pharma
GB Sciences
Serina Therapeutics
Oxford Cannabinoid Technologies
Cannabis Science

Key Products
PPP011
Lenabasum
BX-1
e3D-01
e3D-03
Cannabis Oil
THX-110
Nantheia A1002N5S
Dronabinol
VSN16R
INM-755
BTX 1503
BTX1801
CNTX-6016
TN-TC11G
OWC MGC cream
BTX1702
e3D-05
EPM301
Research programme: Cancer therapeutics
Research programme: cannabinoid-based formulations
PAS-403
PAS-393
Pascal Cannabinoid
Research programme: cannabidiol-combination therapies
Research programme: cannabidiol therapy
Research programme: Synthetic CBD analogs
Supera-CBD
KLS-13019
CNX-004
CNX-005
CNX-006
INM-088
A3AR-based Cannabis Compounds
EPM302
EPM305
EPM306
Cannabinoid containing complex mixtures (CCCM)
Cannabinoid-Based Medical Compound
SER-228
OCT461201
CNX-001
CNX-002
CNX-003
CS-S/BCC-1
Introduction
Executive Summary
Medical Marijuana - Cannabidiol: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
BX-1: Bionorica SE
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
THX-110: Therapix Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early stage products (Phase I/II)
Comparative Analysis
CNTX 6016: Centrexion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Medical Marijuana - Cannabidiol Key Companies
Medical Marijuana - Cannabidiol Key Products
Medical Marijuana - Cannabidiol- Unmet Needs
Medical Marijuana - Cannabidiol- Market Drivers and Barriers
Medical Marijuana - Cannabidiol- Future Perspectives and Conclusion
Medical Marijuana - Cannabidiol Analyst Views
Medical Marijuana - Cannabidiol Key Companies
Appendix

List Of Tables

Table 1 Total Products for Medical Marijuana - Cannabidiol
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Medical Marijuana - Cannabidiol
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Medical Marijuana - Cannabidiol – Pipeline Insight, 2021

DelveInsights, Medical Marijuana - Cannabidiol Pipeline Insight, 2021, report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape. It covers the

USD 2500 View Report

Global Medical Marijuana Market Research Report 2021-2025

Medical marijuana is a term for derivatives of the Cannabis sativa plant that are used to relieve serious and chronic symptoms. In the context of China-US trade war and COVID-19

USD 3200 View Report

Global Medical Marijuana Market Research Report 2021-2025

Medical marijuana is a term for derivatives of the Cannabis sativa plant that are used to relieve serious and chronic symptoms. In the context of China-US trade war and COVID-19

USD 3200 View Report

Medical Marijuana: Consumers Perspectives in the US and UK

Medical Marijuana: Consumers Perspectives in the US and UKIts Medical Marijuana, Consumers Perspectives report combines an extensive survey and analysis of patients perspectives in the US and UK to provide

USD 7995 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available